Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 22
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Cognition Therapeutics Inc
CGTX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.7596
0.013
1.74%
Dern. MÀJ: Oct 22, 11:08 AM
$0.7900
0.0434
5.81%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
Cognition Therapeutics Financials
Cognition Therapeutics (CGTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses of $(0.11) per
Benzinga Newsdesk
PRO
Cognition Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate
Benzinga Newsdesk
PRO
Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of $(0.17) per share
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 76 percent increase over losses of $(0.25) per share
Benzinga Newsdesk
PRO
Cognition Therapeutics Q2 EPS $(0.11), Inline
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 38.89 percent increase over losses of $(0.18) per share from the same period last
Benzinga Newsdesk
